IP Verse

Apixaban Formulations - EP3246021

The patent EP3246021 was granted to Bristol Myers Squibb Ireland on Nov 13, 2019. The application was originally filed on Feb 24, 2011 under application number EP17175864A. The patent is currently recorded with a legal status of "Revoked".

EP3246021

BRISTOL MYERS SQUIBB IRELAND
Application Number
EP17175864A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Nov 13, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (12)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELAug 13, 2020KERNEBECKADMISSIBLE
INTAS PHARMACEUTICALSAug 12, 2020ACCORD HEALTHCAREWITHDRAWN
GENERICS UKAug 10, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
ALFRED E TIEFENBACHERAug 7, 2020HAMM & WITTKOPPADMISSIBLE
WITTKOPPAug 7, 2020HAMM & WITTKOPPADMISSIBLE
KUTZENBERGER WOLFF & PARTNERAug 6, 2020KUTZENBERGER WOLFF & PARTNERADMISSIBLE
POLPHARMAAug 6, 2020ELKINGTON AND FIFEADMISSIBLE
VON SEEBACHAug 6, 2020HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSAug 4, 2020D YOUNGADMISSIBLE
ZENTIVA KSAug 4, 2020HOFFMANN EITLEADMISSIBLE
SANDOZAug 3, 2020KRAUS & LEDERER PARTGMBBADMISSIBLE
KRKAAug 3, 2020HOEFER & PARTNER PATENTANWALTE MBBWITHDRAWN

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006069258
DESCRIPTIONUS6967208
EXAMINATIONWO2008031782
OPPOSITIONEP2538925
OPPOSITIONUS2006069258
OPPOSITIONUS2006160841
OPPOSITIONUS2007259913
OPPOSITIONUS2009291913
OPPOSITIONUS6967208
OPPOSITIONUS7396932
OPPOSITIONWO2006108643
OPPOSITIONWO2007001385
OPPOSITIONWO2007022165
OPPOSITIONWO2008031782
OPPOSITIONWO2009135947
OPPOSITIONWO2010003811
OPPOSITIONWO2010147978
OPPOSITIONWO2011106478
SEARCHUS2006160841
SEARCHWO2010147978
SEARCHWO2011106478

Non-Patent Literature (NPL) Citations (104) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMIDON, G. L. et al., Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420-
OPPOSITION- "<429> Light Diffraction measurement of Particle Size", US PHARMACOPOEIA, USP, vol. 38, XP055640457-
OPPOSITION- Alan Rawle, "BASIC PRINCIPLES OF PARTICLE SIZE ANALYSIS", Malvern Technical Paper, UK, (19930101), no. MRK034, pages 1 - 8, XP002772489-
OPPOSITION- Amidon, Et Al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharmaceutical Research, (19950101), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- AMIDON et al., "Biopharmaceutics Classification System", Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420, XP055640443-
OPPOSITION- Amidon; Et Al, Developing solid oral dosage forms: Pharmaceutical Theory and Practice, Academic Press, (20090000), pages 163-167 , 414 - 416, XP055641338-
OPPOSITION- Amidon Et Al., "Particle, Powder, and Compact Characterization", Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009, (20090130), Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009, (20160818), XP055296127-
OPPOSITION- AMIDON, G. L. et al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharmaceutical Research, (19950000), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- Amidon Gregory E., Deanna P.J.; Mudie Deanna, "Chap 8.Particle, Powder, and Compact Characterization and Chap18.Integration of physical, chemical, mechanical and biopharmaceutical properties in solid oral dosage form development", Amidon Gregory E., Deanna P.J.; Mudie Deanna, Qiu Yihong, Developing solid oral dosage forms : pharmaceutical theory and practice, Burlington, MA, USA, Elsevier/Academic Press, (20090101), pages 163 - 167 - 414 - 416, ISBN 978-0-444-53242-8, XP055829222-
OPPOSITION- ANNUAR N HAFIZAH HJ, TAN K S, OLOFINJANA A, "EFFECTS OF SAMPLE CONDITIONS IN MULTI-PARTICLE SIZE ANALYSIS USING LASER DIFFRACTION TECHNIQUE", Scientia Bruneiana : official journal of the Faculty of Science, Universiti Brunei Darussalam., (20100101), vol. 11, pages 19 - 26, XP003035190-
OPPOSITION- Anonymous, "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation - Tabular View - ClinicalTrials.gov", ClinicalTrials.gov NCT00412984, (20130927), URL: https://clinicaltrials.gov/ct2/show/record/NCT00412984?term=NCT00412984&rank= 1, XP055323941-
OPPOSITION- Anonymous, "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", ClinicalTrials.gov, NCT00320255, (20100218), pages 1 - 2, XP055638473-
OPPOSITION- Anonymous, "Chapter 429: Light Diffraction measurement of Particle Size", US pharmacopoeia, USP 38, (20150501), pages 295 - 299, US pharmacopoeia, USP 38, (20191108), XP055640457-
OPPOSITION- Anonymous, "COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE INVESTIGATION OF BIOEQUIVALENCE", European Medicines Agency / Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/Corr **, (20100120), pages 1 - 27, XP055754045-
OPPOSITION- Anonymous, "Committee of Medicial Products for Human Use (CHMP), Guidelines on the Investigation of Bioequivalence", European medicines Agency / Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/Corr **, (20100120), pages 1 - 27, XP055754045-
OPPOSITION- anonymous, "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", ClinicalTrials.gov NCT00633893,, (20100218), pages 1 - 4, XP055640663-
OPPOSITION- Anonymous, "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", ClinicalTrials.gov NCT00633893,, (20100218), URL: https://clinicaltrials.gov/archive/NCT00633893/2010_02_18, XP055640663-
OPPOSITION- Anonymous, "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", Clinical Trials.gov, NCT00643201, (20100218), URL: https://clinicaltrials.gov/archive/NCT00643201 /2010_02_18, XP055640665-
OPPOSITION- Anonymous, "EMA Assessment report for Eliquis", European Medicines Agency, (20090201), pages 1 - 62, XP055829271-
OPPOSITION- Anonymous, "Guidance for industry - Dissolution testing of immediate release solid oral dosage forms", FDA, (19970800), URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pd, XP055253855-
OPPOSITION- Anonymous, "GUIDANCE FOR INDUSTRY Waiver of In Vivo Bioavailability and Bioequivalence Studies for lmmediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", U.S. FDA,, (20000000), pages 1 - 13, XP055634962-
OPPOSITION- Anonymous, "GUIDANCE FOR INDUSTRY Waiver of In Vivo Bioavailability and Bioequivalence Studies for lmmediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", U.S. FDA, (20000801), pages 1 - 13, XP055634962-
OPPOSITION- Anonymous, "Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", European Pharmacopoeia, (20070723), pages 311 - 314, XP055638472-
OPPOSITION- Anonymous, "The Biopharmaceutics Classification System (BCS) Guidance", FDA U.S. Food & Drug,, (20160000), URL: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm, XP055308403-
OPPOSITION- AULTON, Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 647 - 653-
OPPOSITION- "Bioavailability - physicochemical and dosage form factors", Aulton M E; Ashford M, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition,, (20070000), pages 286-291 ; 443 - 449, XP055308287-
OPPOSITION- COUNCIL OF EUROPE EUROPEAN (COE), "EUROPEAN PHARMACOPOEIA 6TH EDITION", EUROPEAN PHARMACOPOEIA,, (20070723), pages 311 - 314, XP003035191-
OPPOSITION- D. A. WADKE et al., Pharmaceutical dosage forms: Tablets, (19890000), vol. 1, pages 1 - 9, XP009184711-
OPPOSITION- Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, "CHAPTER 1: Preformulation Testing", Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, LIEBERMAN H.A.; LACHMAN L.; SCHAWARTZ J.B., Pharmaceutical Dosage Forms: Tablets, US, Marcel Dekker, (19890101), vol. 1, pages 1 - 73, ISBN 978-0-8247-8044-9, XP009184711-
OPPOSITION- "Dissolution", Joseph P Remington, Remington: the science and practice of pharmacy, Mack Publishing Company, Easton, Pennsylvania, vol. I, page 2pp, 595, XP055282825-
OPPOSITION- DRESSMAN J et al., "The BCS: Where Do We Go from Here?", Pharm Tech, (20010700), pages 68 - 76, XP055308304-
OPPOSITION- EDWARD RUDNIC, JOSEPH B SCHWARTZ, "ORAL SOLID DOSAGE FORMS", EDWARD RUDNIC, JOSEPH B SCHWARTZ, ALFONSO R GENNARO, REMINGTON'S PHARMACEUTICAL SCIENCES ED. 18TH, US, MACK PUBLISHING CO., (19900101), pages I - 1633-1665, XP003035751-
OPPOSITION- European Pharmacopoeia, (20080000), pages 4759 - 4765-
OPPOSITION- Experimental data submitted in the opposition proceedings concerning EP 15190823.3-
OPPOSITION- "Factors Affecting Drug Absorption", Leon Lachman; Herbert A Lieberman and Joseph L Kanig, THEORY AND PRACTICE OF INDUSTRIAL PHARMACY third edition,, Lea & Febiger, Philadelpia, (19860000), pages 221 - 222, XP003032295-
OPPOSITION- "Factors That Influence Dissolution Testing", Banakar U V, Pharmaceutical Dissolution Testing, (19920000), pages 136-137 ; 144 - 145, XP055308585-
OPPOSITION- Frost; C; Et Al, "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", Journal of Thromb. Haemost, (20170709), XP055640220-
OPPOSITION- Frost, C., Et Al, "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. Thromb. Haemost, (20070709), XP055640220-
OPPOSITION- Frost, C., Et Al, "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. Thromb. Haemost, (20170709), XP055640220-
OPPOSITION- FROST, C. et al., "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. Thromb. Haemost, (20170709), XP055640220-
OPPOSITION- "Gastrointestinal Absorption - Physicochemical Considerations", Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, fourth edition,, Lea& Febiger, (19910000), page 2pp, 51, XP055282823-
OPPOSITION- G. L. AMIDON et al., "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailabi/ity", Pharmaceutical Resear ch, (19950000), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- Heinz Sucker Et Al, Pharmazeutische Technologie, 2. Auflage, Georg Thieme Verlag, (19910000), pages 158 - 161, XP055308164-
OPPOSITION- Heinz Sucker Et Al., "Pharmazeutische Technologie", Pharmazeutische Technologie, 2. Auflage, Georg Thieme Verlag, (19910101), pages 158 - 161, ISBN 978-3-13-395802-8, XP055308164-
OPPOSITION- INTERNATIONAL STANDARD ISO 13320-1, XP009127188-
OPPOSITION- James Swarbrick Et Al., "Tablet Formulation", Encyclopedia of Pharmaceutical Technology, 2nd edition, (20020101), pages 2701 - 2712, ISBN 978-0-8247-2824-3, XP055308380-
OPPOSITION- JAMES WELLS, "PHARMACEUTICAL PREFORMULATION: THE PHYSICOCHEMICAL PROPERTIES OF DRUG SUBSTANCES", JAMES WELLS, AULTON M E, PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2,, CHURCHILL LIVIGSTONE, (20020000), pages 113 - 138, XP003035880-
OPPOSITION- J. DRESSMANN et al., "The BCS: Where Do We Go from Here", Pharmaceutical Technology, (20010700), XP055308304-
OPPOSITION- Jennifer Dressman, "The BCS: Where Do We Go from Here?", Pharm Tech, (20010701), pages 68 - 76, XP055308304-
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825-
OPPOSITION- K. H. Bauer Et Al., "Pharmazeutische Technologie", Pharmazeutische Technologie, (19970101), pages 209 - 210, 365, ISBN 978-3-7741-0638-3, XP055308591-
OPPOSITION- Kurt H Bauer, Pharmazeutische Technologie, (19970000), pages 209 - 210, 365, XP055308591-
OPPOSITION- Leon Lachmann, Et Al, "The Theory and Practice of Industrial Pharmacy, third edition", Philadelphia, Lea & Febiger, (19860101), pages 221 - 222, XP055733214-
OPPOSITION- Leon Lachmann, Et Al, The Theory and Practice of Industrial Pharmacy, third edition, Philadelphia, Lea & Febiger, (19860101), pages 221 - 222, XP055733214-
OPPOSITION- M. E. Aulton, M. Ashford, "Bioavailability - physicochemical and dosage form factors", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, (20070101), pages 286-291 , - 443-449, ISBN 978-0-443-10107-6, XP055308287-
OPPOSITION- M. E. Aulton, "Pharmaceutics The Science of Dosage Form Design, second edition", Pharmaceutics The Science of Dosage Form Design, second edition, (20020101), pages 23 - 29, XP055308566-
OPPOSITION- Michael E Aulton, "Pharmaceutics: The Science of Dosage Form Design. Excerpt", (19880101), pages 1 - 173, XP055734912-
OPPOSITION- Milo Gibaldi, "Gastrointestinal Absorption - Physicochemical Considerations", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, Lea& Febiger, (19910101), page 2pp, 51, ISBN 978-0-8121-1346-4, XP055282823-
OPPOSITION- M.R. Lassen, B. L. Davidson, A. Gallus, G. Pineo, J. Ansell, D . Deitchman, "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement1", Journal of Thrombosis and Haemostasis, (2007), vol. 5, pages 2368 - 2375, XP055754069-
OPPOSITION- NCT00412984, URL: https://clinicaltrials. gov/ct2/show/record/NCT00412984?term= NCT00412984&rank=1-
OPPOSITION- "Preformulation Testing", Liebermann H A; Et Al, Pharmaceutical Dosage Forms. 2nd ed. Vol 1,, (19890000), pages 1 - 24, XP055640656-
OPPOSITION- Rudnic E M, Kottke M K, "CHAPTER 10: Tablet Dosage Forms", Rudnic E M, Kottke M K, Gilbert S Banker, Christopher T Rhodes (eds.), Modern Pharmaceutics (third edition), Marcel Dekker, (19960101), pages 333 - 359, ISBN 0-8247-9371-4, XP009184716-
OPPOSITION- Rudnic E M, Kottke M K, "CHAPTER 10: Tablet Dosage Forms", Rudnic E M, Kottke M K, Gilbert S Banker, Christopher T Rhodes (eds.), Modern Pharmaceutics (third edition), Marcel Dekker, (19960101), pages 333 - 394, ISBN 0-8247-9371-4, XP009184716-
OPPOSITION- Rudnic E M; Kottke M K, "CHAPTER 10: Tablet Dosage Forms", Rudnic E M; Kottke M K, Gilbert S Banker; Christopher T Rhodes, Modern Pharmaceutics (third edition),, Marcel Dekker, (19960000), pages 335 - 359, XP009184716-
OPPOSITION- RUDNIC E, SCHWARTZ J B, "ORAL SOLID DOSAGE FORMS", Journal of Pharmaceutical Sciences, US, (19900101), vol. 89, ISSN 0022-3549, pages 1633 - 1665, XP002950573-
OPPOSITION- "Solids", David Attwood, Alexander T Florence, PHYSICAL PHARMACY, Pharmaceutical Press, (20080000), page 2pp, 7, XP055754273-
OPPOSITION- Stojanovic Z.; Markovic S., "determination of particle size distributions by laser diffraction", Technics - New Materials, (20120101), pages 11 - 20, Technics - New Materials, XP055307143-
OPPOSITION- "Tablet Formulation", James Swarbrick Et Al, Encyclopedia of Pharmaceutical Technology, 2nd edition,, Marcel Dekker, Inc.,, (20020000), vol. 3, pages 2701 - 2712, XP055308380-
OPPOSITION- Us Pharmacopoeia, "Chapter 429: Light Diffraction Measurement of Particle Size", (20150501), pages 294 - 299, XP055821992-
OPPOSITION- U. V. Banakar, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920101), pages 136 - 145, ISBN 978-0-8247-8567-3, XP055308585-
OPPOSITION- W.A. Ritschel, A.Bauer-Brandl, Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Editio Cantor Verlag, (20020000), pages 2pp, 122 ; 226-229 ; 260 - 266, XP055754371-
OPPOSITION- W.A. Ritschel, A.Bauer-Brandl, "Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung /Passage/", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Editio Cantor Verlag, (20020101), pages 2pp, 122, 226 - 266, XP055754371-
OPPOSITION- W. A. RITSCHEL et al., Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, (20020000), pages 235 - 241 , 256-259-
OPPOSITION- Y. Tusme Et Al., "the biowaiver extension for BCS Class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate release drugs predicted by computer simulation", Molecular Pharmaceutics, (20100101), pages 1235 - 1243, Molecular Pharmaceutics, (20161007), XP055308518-
OPPOSITION- Zheng, "overview of dry granulation processes and equipment design", Formulation and analytical development for low-dose oral drug products, Wiley, (20090101), pages 119 - 122, XP055765171-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size by Laser Diffraction", Technics - New materials, (20120000), vol. 21, pages 11 - 20, XP055177703-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics - New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics-New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVICET AL., TECHNICS-NEW MATERIALS, vol. 21, 2012, pages 11 - 20, XP055177703-
OPPOSITION- Dressman J B; Amidon G L; Fleisher D, "Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds", Journal of Pharmaceutical Sciences, (19850501), vol. 74, no. 5, pages 588 - 589, XP055308397
OPPOSITION- J.B. Dressman, G.L. Amidon, D. Fleisher, "Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds", Journal of Pharmaceutical Sciences, US, (19850501), vol. 74, no. 5, doi:10.1002/jps.2600740523, ISSN 0022-3549, pages 588 - 589, XP055308397
OPPOSITION- Stegemann S; Leveiller F; Franchi D; De Jong H; Lindén H, "When poor solubility becomes an issue: From early stage to proof of concept", Capsugel,, (20070801), pages 1 - 19, XP055634955
OPPOSITION- Stegemann, S. Leveiller, F. Franchi, D. de Jong, H. Linden, H., "When poor solubility becomes an issue: From early stage to proof of concept", European Journal of Pharmaceutical Sciences, ELSEVIER, AMSTERDAM., NL, NL, (20070719), vol. 31, no. 5, doi:10.1016/j.ejps.2007.05.110, ISSN 0928-0987, pages 249 - 261, XP022163590
OPPOSITION- Papadopoulou, V. ; Valsami, G. ; Dokoumetzidis, A. ; Macheras, P., "Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples", INTERNATIONAL JOURNAL OF PHARMACEUTICS, NL, (20080901), vol. 361, no. 1-2, doi:10.1016/j.ijpharm.2008.05.021, ISSN 0378-5173, pages 70 - 77, XP023316061
OPPOSITION- Henning H Blume, Barbara S Schug, "The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver?", European Journal of Pharmaceutical Sciences, NL, (19991201), vol. 9, no. 2, doi:10.1016/S0928-0987(99)00076-7, ISSN 0928-0987, pages 117 - 121, XP055308358
OPPOSITION- H. H. BLUME et al., "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA / BE waiver?", European Journal of Pharmaceutical Sciences, (19990000), vol. 9, doi:10.1016/S0928-0987(99)00076-7, pages 117 - 121, XP055308358
OPPOSITION- D. J. PINTO, "Discovery of 1 -(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1 -yl)phenyl)- 4,5,6,7-tetrahydro-1 H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS- 562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. Med. Chem., (20070000), vol. 50, doi:10.1021/jm070245n, pages 5339 - 5356, XP007915445
OPPOSITION- Pinto D; ET AL, "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", Journal of Medicinal Chemistry, (20070000), vol. 50, pages 5339 - 5356, XP007915445
OPPOSITION- Pinto D; ET AL, "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", Journal of Medicinal Chemistry,, (20070000), vol. 50, pages 5339 - 5356, XP007915445
OPPOSITION- Pinto D, et al, "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", Journal of Medicinal Chemistry, American Chemical Society, (20070101), vol. 50, doi:10.1021/jm070245n, ISSN 0022-2623, pages 5339 - 5356, XP007915445
OPPOSITION- Lawrence X Yu; Amidon Gordon L; Polli James E; Zhao Hong; Conner Dale P; Shah Vinod P; Lesko Lawrence J; Chen Mei-Ling; Lee Vincent H L; Hussain Ajaz S, "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", Pharmaceutical Research,, (20020000), vol. 19, no. 7, pages 921 - 925, XP055308362
OPPOSITION- Lawrence X Yu, Amidon Gordon L, Polli James E, Zhao Hong, Conner Dale P, Shah Vinod P, Lesko Lawrence J, Chen Mei-Ling, Lee Vincent H L, Hussain Ajaz S, "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", Pharmaceutical Research, (20020701), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- L. X. YU et al., "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions1", Pharmaceutical Research, (20020707), vol. 19, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- Michael Rud Lassen, Gary E. Raskob, Alexander Gallus, Graham Pineo, Dalei Chen, Ronald J. Portman, "Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement", New England Journal of Medicine, Massachusetts Medical Society, US, US, (20090806), vol. 361, no. 6, doi:10.1056/NEJMoa0810773, ISSN 0028-4793, pages 594 - 604, XP055308399
OPPOSITION- Christopher B. Granger, John H. Alexander, John J.V. Mcmurray, Renato D. Lopes, Elaine M. Hylek, Michael Hanna, Hussein R. Al-Khalidi, Jack Ansell, Dan Atar, Alvaro Avezum, M. Cecilia Bahit, Rafael Diaz, J. Donald Easton, Justin A. Ezekowitz, Greg Flaker, David Garcia, Margarida Geraldes, Bernard J. Gersh, Sergey Golitsyn, Shinya Goto, Antonio G. Hermosillo, Stefan H. Hohnloser, John Horowitz, Puneet Mohan, Petr Jansky, Basil S. Lewis, Jose Luis Lopez-Sendon, Prem Pais, Alexander Parkhomenko, Freek W.A. Verheugt, Jun Zhu, Lars Wallentin, "Apixaban versus Warfarin in Patients with Atrial Fibrillation", New England Journal of Medicine, Massachusetts Medical Society, US, US, (20110915), vol. 365, no. 11, doi:10.1056/NEJMoa1107039, ISSN 0028-4793, pages 981 - 992, XP055308595
OPPOSITION- P. BOWEN, "Particle Size Distribution Measurement from Millimeters to Manometers and from Rods to Platelets", Journal of Dispersion Science and Technology, (20020000), vol. 23, pages 631 , 632 , 647 - 652, XP009102859
OPPOSITION- Georgia Charkoftaki, Et Al, "Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, COPENHAGEN, DK, (20100301), vol. 106, no. 3, doi:10.1111/j.1742-7843.2009.00506.x, ISSN 1742-7835, pages 168 - 172, XP055765163
OPPOSITION- TURPIE ALEXANDER G G, "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", Arteriosclerosis, thrombosis, and vascular biology, Lippincott, Williams & Wilkins, (20070601), vol. 27, no. 6, doi:10.1161/ATVBAHA.107.139402, ISSN 1079-5642, pages 1238 - 1247, XP002672841
OPPOSITION- Anonymous, "Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome : Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", Circulation, American Heart Association, US, US, (20090609), vol. 119, no. 22, doi:10.1161/CIRCULATIONAHA.108.832139, ISSN 0009-7322, pages 2877 - 2885, XP055636386
OPPOSITION- "Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination with Antiplatelet After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", Circulation, (20090000), vol. 119, no. 22, pages 2877 - 85, XP055636386
OPPOSITION- Yu Lawrence X.; Ellison Christopher D.; Conner Dale P.; Lesko Larry J.; Hussain Ajaz S., "Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs", AAPS Pharm Sci, New York, (20010901), vol. 3, no. 3, doi:10.1208/ps030324, pages 1 - 7, XP035718572
OPPOSITION- Yu Lawrence X.; Ellison Christopher D.; Conner Dale P.; Lesko Larry J.; Hussain Ajaz S., "Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs", AAPS PharmSci, Springer New York, New York, New York, (20010901), vol. 3, no. 3, doi:10.1208/ps030324, pages 86 - 92, XP035718572
OPPOSITION- Cook Jack; Addicks William; Wu Yunhui Henry, "Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View", The AAPS Journal, (20080524), vol. 10, no. 2, pages 306 - 310, XP035718954
OPPOSITION- Kylie Lepic; Mark Crowther, "New Anticoagulants for the Prevention of Thromboembolism", Current Pharmaceutical Design, (20100000), vol. 16, pages 3472 - 3474, XP055308375

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents